Drug profile · INN
ublituximab
BRIUMVI
ublituximab (BRIUMVI) is a b-lymphocyte antigen cd20 binding agent. Associated with NEURAXPHARM AUSTRALIA PTY LIMITED.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04
Patents linked 0
Pipeline programs 19
News articles 0
Drug details — ublituximab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 19
- Data quality
- 0.83
Quick answer
ublituximab (BRIUMVI) is a b-lymphocyte antigen cd20 binding agent. Associated with NEURAXPHARM AUSTRALIA PTY LIMITED.
Key facts
INN ublituximab
Brand BRIUMVI
Mechanism B-lymphocyte antigen CD20 binding agent
Target B-lymphocyte antigen CD20
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04
Originator NEURAXPHARM AUSTRALIA PTY LIMITED
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Primary target: B-lymphocyte antigen CD20
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ublituximab?
ublituximab (BRIUMVI) is a b-lymphocyte antigen cd20 binding agent. Associated with NEURAXPHARM AUSTRALIA PTY LIMITED.
What is the brand name for ublituximab?
BRIUMVI is a marketed brand name for ublituximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.